Tuberculosis vaccines - perspectives from the NIH/NIAID Mycobacteria vaccine testing program.

Abstract

The development of novel vaccine candidates against infections with Mycobacterium tuberculosis has highlighted our limited understanding of immune mechanisms required to kill M. tuberculosis. The induction of a Th1 immunity is vital, but new studies are required to identify other mechanisms that may be necessary. Novel vaccines formulations that invoke effector cells such as innate lymphoid cells may provide an environment that promote effector mechanisms including T cell and B cell mediated immunity. Identifying pathways associated with killing this highly successful infectious agent has become critical to achieving the goal of reducing the global tuberculosis burden.

• Authors: Angelo A Izzo
• Journal: Current opinion in immunology (Curr Opin Immunol) Vol. 47 Pg. 78-84 (Aug 2017) ISSN: 1879-0372 [Electronic] England
• PMID: 28750280 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2017 Elsevier Ltd. All rights reserved.

Chemical References

• Tuberculosis Vaccines

Topics

• Animals
• B-Lymphocytes (immunology)
• Humans
• Immunity, Humoral
• Immunity, Innate
• Lymphocyte Activation
• Lymphocytes (immunology)
• Mycobacterium tuberculosis (immunology)
• National Institute of Allergy and Infectious Diseases (U.S.)
• Th1 Cells (immunology)
• Tuberculosis (immunology, prevention & control)
• Tuberculosis Vaccines (immunology)
• United States